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Purpose/Objective: Verification of the calculated and delivered dose 
trough independent verification of treatment planning system (TPS) 
and in vivo dosimetry are important part of the overall radiotherapy 
quality assurance (QA). The verification of TPS was done according to 
IAEA recommendations and put an emphasis on dosimetry part of the 
treatment planning and delivery processes. In vivo dosimetry was 
implemented as quality assurance procedure for patient treatment 
verification. 
Materials and Methods: Verification of TPS was done with 
anthropomorphic phantom which was later also used for in vivo 
measurements prior to patient measurements. Set of clinical test 
cases suggested by the IAEA, covering a range of typical clinical 
radiation techniques found in 3D conformal radiotherapy treatment 
(3D CRT) was used both for TPS and in vivo dosimetry verification. The 
doses were measured with ion chamber and semiconductor diodes, 
and compared to doses calculated in TPS for interest points for test 
cases and points in build up for entrance in vivo readings. 
Consequently, set of breast patients were checked by in vivo during 
their regular treatments. For patient treatment verification, 
tangential half fields were used and in vivo diodes were placed off 
axis, under large gantry angles, with different wedge types and 
angles. 
Results: The measurements were conducted for 6 MV beam energy 
and advanced calculation algorithm. The differences between the 
measured and calculated doses for all test cases were within the 
tolerance level. The differences of in vivo phantom measurements and 
TPS calculation varied depending on the test type: 0.5% for open field 
case to 5.3% for enhanced dynamic wedge (EDW) test case. In vivo 
measurements conducted for breast patients showed difference of not 
more than 5% in comparison with values calculated by TPS.  
Conclusions: After verification of TPS calculation, dose calibration 
and correction factors for semiconductor diodes were checked and 
prediction for in vivo doses in TPS was verified. The errors of 5 % 
magnitude are common in clinics worldwide and clinical 
implementation of in vivo dosimetry in our clinic has given confidence 
that patients are being treated with prescribed dose. This was 
opportunity to systematically review the uncertainties involved in 
treatment planning and dose delivery processes leading to more 
accurate patient treatment. 
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Purpose/Objective: We investigate how QA criteria relate to 
sensitivity end specificity for increased normal tissue toxicity risk and 
risk of decreased tumour control in rotational therapy for prostate 
cancer. 
Materials and Methods: QA analysis for 8 clinical plans and 160 plans 
with deliberately introduced errors was carried out using ten sets of 
QA criteria. The tumour control probability (TCP), and risk of rectal 
bleeding (NTCP_rectum), were calculated. An unacceptable plan was 
defined as a plan where TCP decreased by more than 2%, or the NTCP 
increased by more than 50%, as compared with the clinical plan. We 
chose the 50% NTCP threshold as the rectum was in the low dose 
region. The sensitivity and specificity for detecting unacceptable 
plans and their sum (S+S) were determined for each QA criteria set. 
The diagnostic quality of the QA criteria was also assessed by 
receiver-operator characteristics curves. For dose difference (DD) = 3 
% and distance to agreement (DTA) = 3 mm; the required percentage 
of gamma smaller than 1 for acceptance (A) was scanned and the 
value of A which maximised S+S was determined. In an iterative 
process TCP and TNCP respectively were varied to find the values 
which corresponded to DD=3%, DTA =3 mm and A = 95 %. 
Results: A set of DD = 3 %; DTA = 3 mm and A = 95 % corresponds to 
ensuring that TCP is > 99 %; and NTCP < 160%; of the clinical values. 
For DD = 3 %; DTA = 3 mm, S+S was maximised for A = 95 %. We could 
not identify a single set of QA parameters that was significantly better 
than the others. However, three of the criteria had a significantly 
lower area under the ROC curve than the best parameter sets.  
Conclusions: A method for relating clinical risk estimates to QA 
parameters has been demonstrated. This method can be used to 
determine A for given DD and DTA values once the relative weights of 
sensitivity and specificity have been chosen by the user. It can also be 
used to determine which values of ΔTCP and ΔNTCP correspond to the 
chosen QA criteria set.  
   
EP-1180   
Dosimetric accuracy assessment of a treatment plan verification 
system for scanned proton beam radiotherapy 
S. Molinelli1, A. Mairani1, A. Mirandola1, G. Vilches Freixas1, T. 
Tessonnier2, M. Ciocca1 
1Fondazione CNAO, Medical Physics, Pavia, Italy  
2Université Joseph Fourier, Medical Physics, Grenoble, France  
 
Purpose/Objective: To assess the accuracy of a three-dimensional 
dose verification technique for patient-specific Quality Assurance (QA) 
in active scanning proton therapy. Critical cases of major deviations 
between treatment planning system (TPS) calculated and measured 
data points are further investigated with Monte Carlo (MC) 
simulations.  
Materials and Methods: Treatment plan verification is performed in a 
water phantom with the simultaneous use of twelve small-volume 
ionization chambers (one data set), aligned in four rows in a way that 
none of them perturbs the other ones. The acceptance threshold is set 
at 5% for both mean deviation between measured and calculated 
doses and one standard deviation, over twelve measurement points. 
Results of 180 data sets, obtained along one year of clinical activity at 
the Italian National Center for Oncological Hadron Therapy (CNAO), 
were analyzed.Data were organized based on tumor site (skull versus 
sacrum) and TPS optimization technique (single field uniform dose 
SFUD versus intensity modulated particle therapy IMPT). A warning 
level was defined for data sets showing more than 30% of single point 
absolute deviations higher than 5% and needing further investigation. 
A MC tool for plan verification in water was implemented to evaluate 
the impact of dose calculation, dose delivery and measurement set-up 
uncertainties on the nine cases resulting out of the warning level.  
Results: All patient-specific quality checks resulted within the 
acceptance threshold. Mean deviation between TPS dose calculation 
and measurement was less than ±3% in 86%of the cases. For targets 
located in the skull region an average higher deviation was found, 
compared to the sacrum region, due to more complex dose patterns 
involved. In addition, the use of a less robust optimization technique, 
such as IMPT compared to SFUD, produced much more scattered 
results and higher single point variation. When all sources of 
uncertainty were accounted for with the MC tool, all the simulated 
cases showed even higher level of agreement, with mean absolute 
deviation ≤ 2% (maximum absolute deviation< 5%). 
Conclusions: Along this first year of clinical activity, the results of all 
patient-specific QA checks performed using ICs in a 3D configuration 
were found within the acceptance threshold. The use of a MC-based 
tool to investigate potential causes of major deviations should be 
further explored, particularly for more complex IMPT plans. 
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Purpose/Objective: This study was performed to examine the effect 
of various factors on the optimization of volumetric modulated arc 
therapy (VMAT) patient specific quality assurance (QA). 
Materials and Methods: Plans were created in eclipse treatment 
planning system (TPS) and measurements were performed in Varian 
Clinac-iX linear accelerator. Fifteen VMAT Plans were compared on 
the basis of type of delivery, number of arcs, complexity (treatment 
site), number of target volumes, and inclusion/exclusion of couch in 
the plans. For the same cases seven field intensity modulated 
radiotherapy (IMRT) plans were also created to compare QA results. 
Planar dose measurements were performed using ImatriXX 2-D array 
system of IBA dosimetry. Percentage of pixels passed the 3%-3 mm 
gamma criterion (% dose difference and distance to agreement-DTA) 
was taken for the comparison. Point dose measurements were also 
performed and the percentage deviation of the calculated doses 
versus measured doses was compared. Student’st-test was performed 
for the statistical analysis of the QA results. 
Results: IMRT plans showed better QA results as compared to double-
arc plans for head & neck site with more than one target volume 
(99.6% vs. 97.91% for the mean percentage of pixels passing the set 
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criterion). The double-arc plans had couch included in the dose 
calculation. Similarly single-arc plans (98.67%), simple pelvic plans 
(99.9%), and single target volume plans (98.8%) showed more % of 
pixels passing the criterion than the complex double-arc plans. Only 
the plans which didn’t include the couch in the dose calculation 
showed poorer results. The p-values in student’s t-test showed 
significant variations in the gamma values in comparisons.  
Conclusions: Optimization of patient specific QA should take into 
account of all the affecting factors like type of delivery, number of 
arcs, complexity (treatment site), number of target volumes, and 
inclusion/exclusionof couch in the plans.  
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Purpose/Objective: Traditional patient specific quality assurance 
(QA) is based on gamma values that may not detect small but 
clinically significant variations between the plan and delivered dose. 
For applications which operate near the limits of machine capabilities 
and tolerance doses, such as hypo fractionated volumetric modulated 
arc therapy (VMAT), dose volume histogram (DVH) based analysis is 
preferred. The purpose of this work is to present the principles of a 
DVH based QA technique using radiochromic film in a cylindrical 
phantom. 
Materials and Methods 
1. A VMAT plan was created for a lung patient with a commercial 
treatment planning system (Varian Eclipse). Commonly such 
plans consist of a clock wise and a counter clockwise 360 degree 
arc. Using the proposed technique requires that each field be 
split into two 180 degree arcs so that we can acquire the 
entrance and exit doses simultaneously on gafchromic film (ISP 
EBT3) surrounding a cylindrical phantom at Dmax.  
2. A Verification Plan (VP) is created in Eclipse for both the patient 
and the phantom. Note that VP has the ability to modify several 
plan parameters such as Monitor Units (MU), Micro Leaf 
Collimator positions, and arc angles corresponding to the plan 
control points. This capability has not been presented or 
exploited in any previous work.  
3. The MUs for one control point in the patient VP were modified 
to represent possible delivery error. The plan was delivered to 
the phantom on a Varian TrueBeam Linac and the film processed 
according to the manufacturers recommendations using only the 
red color component.  
4. Comparison of the planned phantom dose (PPD) and the actual 
measured phantom dose (MPD) in is performed in MATLAB with 
the imaging toolbox. Algorithms compute the gantry angle, field 
size, and the ratio of the measured to plan dose for any 
modified control points.  
5. The measured control point modifications were incorporated 
back into the patient VP and an updated modified patient dose 
distribution computed. DVH tools in Eclipse are used for 
comparison of the original patient plan and modified patient 
plan. Note that all calculations are performed within the same 
treatment planning system thereby avoiding differences due to 
calculation algorithms.  
Results: Experimental studies show that changes in a single control 
point such as shown in Figure 1 can be detected and they can lead to 
significant clinical changes, including maximum dose to a critical 
organ. 
The detail in Figure 1 is sufficient to resolve 2.5 mm MLC leaves. 
The observed intensity pattern differs slightly from the expected dose 
of a single control point. Further investigation is required to see if this 
is due to leaf motion during rotation between control points. 
 
Figure 1. 
Conclusions: We have described a QA technique for DVH comparison 
of a computed patient plan with the actual delivered plan using a 
commercial treatment planning system and measurements with 
radiochromic film in a cylindrical phantom. 
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Purpose/Objective: We investigated a commercial system, consisting 
of the ArcCHECK (AC) dosimeter and 3DVH (Version 2.2, Sun Nuclear 
Corp). This combination allows reconstructing 3D patient dose based 
on measurements. The objective of this work is to study the behaviour 
of the Planned Dose Perturbation (ACPDP) algorithm and to investigate 
its accuracy under different basic situations. 
Materials and Methods: In our scenario the phantom is considered as 
the patient, allowing independent measurements. To investigate the 
performance of ACPDP we introduced three kinds of 'errors' into 
simple reference plans. It was then examined whether ACPDP could 
reproduce the dose of the modified plan, using the (non-modified) 
reference plan as a-priori knowledge and the AC measurements of the 
modified plan. The errors introduced into a homogenous static field 
were (a) an over-dosage (1 to 5%) in areas of different size, and (b) a 
variation of the MLC field width (±2 to ±8 mm). The error (c) was 
introduced into a dynamic arc field (90° to 270°) simulating a 
deviation of MLC position (±2 to ±10 mm) of 1/3 of the leaves. All 
measurements were performed on a Varian CLINAC 2100CD, dose 
calculation in Eclipse (TPS: AAA 10.0.28). Ion chamber (IC) and EBT3 
film were used to establish the TPS as a very accurate reference. 
Results: TPS dose calculation agreed very well with IC (-0.4 to 0.6%) 
and selected AC diodes (-0.8 to 1.3%). Relative film measurements 
confirmed the very accurate TPS calculation of gradients at field 
edges. Error (a) could clearly be found in the dose reconstructed by 
3DVH (agreement within ±0.5%) as long as the 'High Sensitivity' (HS) 
mode of the ACPDP algorithm was used and the area was larger then 
1x1 cm². The error was ignored for smaller areas and with ACPDP in 
'Normal Sensitivity' (NS) mode. The deviation (b) was clearly 
recognized by the AC diodes. Still, almost no influence of the 
measurements could be seen at the field edge in the ACPDP-
calculated dose (HS) based on those measurements. The error was 
either ignored completely or an unrealistic interpolation between 
expected and measured dose was performed (Fig. 1a). Error (c) 
extends the results of (b). Again, although the error was measured, 
ACPDP-calculated dose (HS) shows increasing deviations from the 
expected dose with increasing error. The effect is more pronounced in 
the periphery where the differences exceed 3% for a 2 mm MLC 
displacement and go up to more than 15% for 10 mm. The agreement 
in the phantom centre was better, ranging from 0.8 to 2.9% (Fig. 1b). 
 
